Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 23 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
- 14 Jan 2016 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov.
- 14 May 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.